Aurinia Pharmaceuticals Inc. - 10-Q Summary (Q2 2026)
Business Context and Reporting Period
This report covers the quarterly period ended June 30, 2026. Aurinia Pharmaceuticals Inc. is a biopharmaceutical company focused on autoimmune diseases, primarily commercializing LUPKYNIS (voclosporin) for lupus nephritis. The company also develops aritinercept and completed the acquisition of Kezar Life Sciences, Inc. on May 11, 2026, which is accounted for as an asset acquisition.
Key Financial Metrics
| Metric | Q2 2026 (3 Months) | YTD 2026 (6 Months) | YTD 2025 (6 Months) |
|---|---|---|---|
| Total Revenue | $83.2 million | $160.9 million | $132.5 million |
| Net Product Sales | $79.4 million | $153.0 million | $126.5 million |
| Net Income | $37.4 million | $71.8 million | $44.9 million |
| Diluted EPS | $0.28 | $0.53 | $0.32 |
| Operating Cash Flow (YTD) | $85.1 million | ||
| Cash & Investments (End of Period) | $443.1 million | ||
| Share Repurchases (YTD) | 5.0 million shares for $74.9 million |
Margins: Gross margin for the three and six months ended June 30, 2026, was 92%, compared to 90% and 88% in the same periods of 2025.
Material Changes vs. Prior Period
- Revenue Growth: Total revenue increased 19% in Q2 and 21% YTD compared to 2025, driven by a 19% increase in LUPKYNIS cartons sold to specialty pharmacies.
- Profitability: Net income increased 74% in Q2 and 60% YTD. Operating income rose significantly to $46.3 million (Q2) and $87.8 million (YTD).
- Expense Dynamics:
- R&D: Increased 75% in Q2 and 56% YTD due to higher personnel costs and clinical supply expenses.
- SG&A: Decreased 10% in Q2 and 2% YTD, largely due to reduced share-based compensation from executive departures and forfeited awards.
- Other Income: Shifted from an expense of $9.2 million in Q2 2025 to income of $6.2 million in Q2 2026, primarily due to favorable foreign exchange remeasurement on the Monoplant finance lease.
- Tax Impact: Income tax expense increased significantly (from $0.6M to $11.4M in Q2) because the company utilized its deferred tax assets in late 2025; these assets are no longer available to offset current period expenses.
Guidance, Outlook, and Risks
- Outlook: Management expects SG&A expenses to remain consistent with 2025 levels. R&D expenses are expected to increase as development activities progress. The company expects to fund future operations with existing cash and operating cash flows.
- Acquisition: The Kezar acquisition added $3.7 million in contingent value rights (CVR) liabilities. The acquired IP was expensed immediately.
- Share Repurchase: The company has an active repurchase program with approximately $86.6 million remaining available as of June 30, 2026.
- Risks: No material changes to risk factors were reported. Key risks include the success of commercialization efforts for LUPKYNIS and the ability to control expenses.
Investor Verification Checklist
- Tax Rate Normalization: Verify the sustainability of the ~23% effective tax rate, noting the one-time benefit of releasing the valuation allowance in late 2025.
- FX Sensitivity: Assess the impact of Swiss Franc fluctuations on the Monoplant finance lease liability, which drove a $6.2 million income swing in Q2.
- Kezar Integration: Monitor the realization of value from the Kezar asset acquisition and the potential payout of the $3.7 million CVR liability.
- Share Count: Confirm the impact of ongoing share repurchases (5.0M shares YTD) on future EPS dilution/accretion.
- R&D Spend: Review the trajectory of R&D expenses, which rose sharply to support clinical development of aritinercept and LUPKYNIS combination studies.